Latest news
Incyte Wins EU Approval for Opzelura in Atopic Dermatitis - MyChesCoMyChesCo · Sun, 09 Aug 2026 06:00:00 GMTWeekly Recap: Incyte Q2 revenue surge and Opzelura second EU indication - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTThe Bull Case For Incyte (INCY) Could Change Following New EU Opzelura Atopic Dermatitis Approval - webull.comwebull.com · Mon, 03 Aug 2026 01:38:09 GMTIncyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In? - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 21:09:41 GMTIncyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 07:00:00 GMTIncyte (INCY) Wins European Approval For Opzelura In Adult Atopic Dermatitis - webull.comwebull.com · Fri, 31 Jul 2026 10:31:36 GMTPfizer cues up vitiligo filing for Litfulo after phase 3 win - pharmaphorumpharmaphorum · Thu, 30 Jul 2026 18:50:22 GMTIncyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod - TradingViewTradingView · Wed, 29 Jul 2026 17:22:11 GMT